Type 3 Cyclic Nucleotide Phosphodiesterase (PDE3)

Type 3 cyclic nucleotide phosphodiesterases (PDE3) are a family of enzymes that hydrolyze the second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), thereby regulating their intracellular concentrations and modulating various physiological processes. PDE3 is also known as cGMP-inhibited phosphodiesterase due to its unique regulatory mechanism. Acute use of selective PDE3 inhibitors increases cardiac output via positive inotropic effects. However long-term use raises mortality risk due to arrhythmias/sudden death. Downregulation or dysfunction may contribute to progression of heart failure.

Other names

cGMP-inhibited phosphodiesterase

Selective PDE3 inhibitors increase cardiac output via positive inotropic effects and modulate vasodilation through effects on cAMP/cGMP signaling.